Search

Risperidone microspheres for injection, as the first long-acting injection of the second generation antipsychotic drugs in China, combines the advantages of long-acting dosage forms and atypical antipsychotics, and had accumulated rich clinical application experience for more than ten years, bringing significant clinical benefits to schizophrenia patients. On the basis of the Expert Opinions on Clinical Application of Atypical Long-acting Injection (Risperidone Microspheres for Injection) in 2012, experts organized by Schizophrenia Collaboration Group of the Chinese Psychiatry Society systematically summarized the latest guidelines and evidence-based evidence at home and abroad, and combined with the clinical practice in China, formulated the Expert Consensus on Clinical Application of Risperidone Microspheres for Injection, aiming at improving the scientific and normative clinical use of risperidone microspheres for injection and providing better clinical medication guidance for clinicians. [ABSTRACT FROM AUTHOR]

Lurasidone is a second-generation anti psychotic drug which has a high affinity for dopamine D2, serotonin 5-HT2A and 5-HT7 receptors. Several clinical trials in patients with schizophrenia indicated lurasidone' s effect on improving psychotic symptoms, affective symptoms and cognitive symptoms, and it also manifested fewer side effects on metabolic indicators. Based on the evidence from previous studies on lurasidone and clinical experiences of experts from China Mainland and Taiwan, this experts' advice has been formed with an aim to provide guidance on the use of lurasidone in clinical practice. [ABSTRACT FROM AUTHOR]

Blonanserin is a second-generation atypical antipsychotic agent with potent affinity to dopamine D2 and D3 receptors and serotonin 5-HT2 A receptor,and with low or negligible affinity for adrenergic α1,serotonin5-HT2 C,histamine H1,and muscarinic M1 and M3 receptors.It is effective in both positive and negative symptoms of schizophrenia,and improves some domain of the cognitive symptoms and social functions of patients.Based on the evidences and clinical experiences of several Chinese and Japanese experts,the article aimed to provide a comprehensive,objective,and reasonable medication recommendation for clinical psychiatrists and help patients with schizophrenia to recover and return to society at the earliest. [ABSTRACT FROM AUTHOR]

Eating disorders (EDs) are a kind of chronic disease with high relapse rate and heavy disease burden. Patients with EDS have neurocognitive deficits related to executive function, among which the main manifestations are abnormal attentional bias and inhibitory control. Event-related potential studies are being undertaken to explore the underlying neural mechanism of cognitive abnormalities in EDS. This paper reviews the research of event-related potentials in EDs from the aspect of attentional bias and inhibition control. Suggestions for the future diagnosis and treatment programs based on neurocognitive mechanism are provided. [ABSTRACT FROM AUTHOR]

Objective: To explore the characteristic of cognitive flexibility in young female patients with eating disorders (EDs）,including anorexia nervosa (AN) and bulimia nervosa (BN）,and its relationship with the clinical features of ED. Methods : Ninety-two young female patients with EDs, including 28 patients with AN and 64 patients with BN, and 38 normal controls were enrolled.Cognitive flexibility was assessed with percentage of persistent errors (PPE) and percentage of persistent responses (PPR) of the Wisconsin Card Sorting Test (WCST）,and clinical features of ED by using the Eating Disorder Inventory-1 (EDI-1）.Results:The PPE[ (5.0±4.7) % vs. (2.8±2.8) %,P <0.01] and PPR[ (11.7±7.8) % vs. (6.4±5.9) %,P <0.001] were higher in ED group than in normal control group, but the differences on PPE[ (5.5±5.4) % vs. (5.0±4.5) %,P> 0.05] and PPR[ (11.2±7.8) % vs. (11.1±7.3）%,P> 0.05] between AN and BN groups were not statistically significant. The PPE (r=0.21,P <0.05) and PPR (r=0.27,P <0.01) were positively correlated with the EDI-1 total scores.PPR was positively correlated with the frequency of appetite suppressant use (r=0.28,P <0.05) and skipping several meals (r=0.30,P <0.01) in the ED group. Conclusion: The presence of cognitive flexibility deficits in young female patients with eating disorders, and their correlation with clinical features of eating disorders further support the possibility of being an endophenotype of eating disorders. [ABSTRACT FROM AUTHOR]

Amisulpride, a kind of the second generation antipsychotics, was marketed in China in 2010. A series of clinical research and experience before and after listed, especially the data based on Chinese population, provided evidence for the generalization and application of amisulpride. In order to optimize the clinical application of amisulpride, and improve the prognosis of patients, Expert Advice on the Practical Use of Amisulpride in the Treatment of Schizophrenia is presented here. This advice is based on the recent evidence and clinical experience, for guiding the clinical medication of amisulpride. [ABSTRACT FROM AUTHOR]

Objective: To evaluate the validity and reliability of the Identity and Eating Disorders questionnaire (IDEA) in China. Methods: Totally 187 patients with eating disorders meeting diagnostic criteria of DSM-IV and 60 normal controls were assessed with IDEA and the Eating Disorder Inventory (EDI-1). Thirty patients were re¬tested with IDEA within 2 weeks . Results: The 4 factors were extracted from the items by exploratory factor analy¬ sis with cumulative vaiance being 63.3%. There were 3 items drifting, which were deleted during later analy¬sis .The intraclass correlation coefficient of IDEA and EDI-1 was 0 . 8 6 . The total scores and the 4 subscale scores of IDEA were higher in the patient group than in the control group (Ps <0. 001). The Cronbach a coefficients of the I¬DEA was 0. 95, and the splitting half-reliability coefficient was 0. 93. Pearson correlation coefficient of retest was 0. 86. Conclusion: The Chinese version of IDEAhas good validity and reliability for evaluating eating disorders and related psychological characteristics in patients with eating disorders. [ABSTRACT FROM AUTHOR]

Fluvoxamine, one of the SSRIs, possesses specifically pharmacology mechanism and shows satisfactory efficacy in the treatment of major depressive disorder, obsessive-compulsive disorder and anxiety disorder. In order to provide an objective and comprehensive medication reference and guide to clinical psychiatrists in using fluvoxamine with more standardly manner, the "Experts'advice on fluvoxamine in the clinical practice" was formed by psychiatric expert group with evidence-based medical data and clinical experiences. [ABSTRACT FROM AUTHOR]

Objective: To explore clinical and psychological characteristics of anorexia nervosa restricting type (ANR) and anorexia nervosa binge-purging type (ANBP) subtypes of female anorexia nervosa (AN). Methods: A total of 269 ANR and 151 ANBP female patients were recruited and instructed to complete Eating Disorder Ques- tionnaire (EDQ) and Eating Disorder Inventory-1 (EDI-1). The demography traits, BMI and EDI-1 factors scores were respectively compared between ANR and ANBP patients. Furthermore, the influencing factors to sub-typing of anorexia were analyzed with logistics regression. Results: The statistical difference in demography traits was not found between two subtypes of AN after age-matched. The ANBP group had higher BMI but lower expected BMI than the ANR group. The total score and all sub-scales scores of EDI-1 were significantly higher in ANBP group than in the ANR group. Logistics regression results showed that bulimia, ineffectiveness and maturity fears were the significant predictors of subtypes of female anorexia, namely, higher scores of bulimia and ineffectiveness were as- sociated with ANBP subtype, but higher scores of maturity fears was associated with ANR subtype. Conclusions: It suggests that bulimia, ineffectiveness and maturity fears may be powerful predictive factors to sub-typing of female anorexia nervosa, and the psychological characteristics associated with eating disorders are different between ANBP and ANR patients. [ABSTRACT FROM AUTHOR]

Objective: To analyze related factors to the informed consent competency of patients with schizophrenia. Methods: Subjects were divided into two groups, namely one group including 100 patients with schizophrenia and the other group including 28 heathy controls. Patients with schizophrenia were administrated from community rehabilitation units and The Sixth Hospital of Peking University, diagnosed with the Diagnostic and Statistical Manual of mental disorder, Fourth Edition ( DSM-IV). Informed consent competency of subjects were evaluated with the Chinese Mandarin Version of MacArhur Competence Assessment Tool for Clinical Research. Psychiatric symptoms, intelligence quotient and severity of disease were accessed individually with the Positive and Negative Symptom Scale (PANSS), Wechsler Abbreviated Scale of Intelligence (WASI) and Clinical General Impression- Severity Scale (CGI-S). Logistic regression analysis model was used to analyze the risk factors of impaired informed consent competency in schizophrenia. Results: The rates of absent, impaired and adequate informed consent competency were 26. 0% (26/100), 47. 0% (47/100) and 27 . 0% (27/100) in schizophrenia group, and 3 . 6% (1/28)，57. 1% (16/28) and 39. 3% (11/28) in control group. Rate of absent informed consent competency was higher in schizophrenia group than that in control group (26. 0% vs. 3. 6% , P <0. 01). There were no statistic significant differences in rates of impaired and adequate informed consent competency between two groups (both P > 0. 05). Results of logistic regression analysis showed that schizophrenic patients with higher scores of positive subscale ( OR = 1. 15), negative subscale ( OR = 1. 23) and CGI-S ( OR = 1. 57) had more tendency to impaired capacity. Higher education level (O R =0. 73) and higher scores of IQ (O R = 0. 92) had less risks for that. Conclusion: Competency of informed consent in schizophrenia may be worse than that in health control. Patients with schizophrenia with impaired informed consent competency may have more serious of positive, negative psycWatric symptoms and higher severity of disease. Higher level of education and IQ scores may reduce the risk of impaired informed consent competency. [ABSTRACT FROM AUTHOR]